The data indicate that the 3,5-disubstituted compounds were NR4A1 antagonists and we hypothesized that their in vivo activity as inhibitors of tumor growth would be similar to or greater than the buttressed analogs of CDIM8. The gene discussed is NR4A1; the disease is neoplasm.